Highlights of 10th St. Gallen Breast Cancer Conference: Systemic Adjuvant Treatment.
- Author:
Seung Il KIM
1
;
Ho yong PARK
Author Information
- Publication Type:Review
- Keywords: St. Gallen conference 2007; Endocrine therapy; Chemotherapy
- MeSH: Breast Neoplasms*; Breast*; Congresses as Topic; Consensus; Drug Therapy; Humans; Risk Assessment; Trastuzumab
- From:Journal of Breast Cancer 2007;10(1):1-9
- CountryRepublic of Korea
- Language:Korean
- Abstract: The 10th St. Gallen International Conference- Primary Therapy of Early Breast Cancer was held in March 2007. The St. Gallen Conferences has focused on reaching expert consensus for patient treatment selection. Three categories were affirmed by responsiveness of endocrine treatment- endocrine responsive, endocrine responsive uncertain, endocrine non-responsive. Risk assessment will be similar than previous meeting (9th meeting) - low, intermediate, and high risk categories. The Panel recommended that patients be offered endocrine therapy or trastuzumab according to endocrine responsiveness or HER2 status. Chemotherapy offered to patients according to risk assessment. For patients with endocrine responsive and HER2 negative, selection of patient for chemotherapy is major challenge. The Panel of Expert attempted to answer many questions- endocrine therapy, chemotherapy, anti-HER2 therapy, and radiation therapy. This report focused on new information related to the best use of endocrine therapy and chemotherapy.
